(Q37405065)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19254941%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

review article

1 reference

title

Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19254941%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

main subject

metastatic breast cancer

1 reference

P A Canney

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19254941%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

L Y Dirix

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19254941%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

2 March 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19254941%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19254941%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19254941%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19254941%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

615-620

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19254941%20AND%20SRC:MED&resulttype=core&format=json

Effect of screening and adjuvant therapy on mortality from breast cancer

22 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

Continuing with letrozole offers greater benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

Breast cancer and NSAID use: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

Identification and characterization of a cAMP-responsive element in the region upstream from promoter 1.3 of the human aromatase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

Aromatase in the normal breast and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

Reduced expression of cyclooxygenase-2 in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

Fissurectomy and isosorbide dinitrate for chronic fissure in ano not responding to conservative treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN693